Medicina
Departamento
University of Virginia
Charlottesville, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Virginia (24)
2021
-
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study
Journal of Clinical Oncology, Vol. 39, Núm. 33, pp. 3725-3736
-
Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer
Human Genetics and Genomics Advances, Vol. 2, Núm. 3
-
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
European Journal of Cancer, Vol. 148, pp. 411-421
2019
-
Publisher Correction: Shared heritability and functional enrichment across six solid cancers (Nature Communications, (2019), 10, 1, (431), 10.1038/s41467-018-08054-4)
Nature Communications
-
Shared heritability and functional enrichment across six solid cancers
Nature Communications, Vol. 10, Núm. 1
2018
-
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
The Lancet Neurology, Vol. 17, Núm. 5, pp. 405-415
2017
-
Primary care requests for anaemia chemistry tests in Spain: Potential iron, transferrin and folate over-requesting
Journal of Clinical Pathology, Vol. 70, Núm. 9, pp. 760-765
2016
-
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
The Lancet, Vol. 387, Núm. 10031, pp. 1909-1920
-
Effect of diastolic dysfunction on postoperative outcomes after cardiovascular surgery: A systematic review and meta-analysis
Journal of Thoracic and Cardiovascular Surgery, Vol. 152, Núm. 4, pp. 1142-1153
2010
-
Identifying predictors of central nervous system disease in solid organ transplant recipientswith cryptococcosis
Transplantation, Vol. 89, Núm. 1, pp. 69-74
-
Unrecognized pretransplant and donor-derived cryptococcal disease in organ transplant recipients
Clinical Infectious Diseases, Vol. 51, Núm. 9, pp. 1062-1069
2009
-
Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis
Clinical Infectious Diseases, Vol. 49, Núm. 11, pp. 1721-1728
-
Pulmonary zygomycosis in solid organ transplant recipients in the current era
American Journal of Transplantation, Vol. 9, Núm. 9, pp. 2166-2171
-
Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome
Journal of Infectious Diseases, Vol. 200, Núm. 6, pp. 1002-1011
2008
-
Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: Correlation with outcome in solid organ transplant recipients with cryptococcosis
Antimicrobial Agents and Chemotherapy, Vol. 52, Núm. 2, pp. 735-738
-
Central nervous system cryptococcosis in solid organ transplant recipients: Clinical relevance of abnormal neuroimaging findings
Transplantation, Vol. 86, Núm. 5, pp. 647-651
-
Pulmonary cryptococcosis in solid organ transplant recipients: Clinical relevance of serum cryptococcal antigen
Clinical Infectious Diseases, Vol. 46, Núm. 2
2007
-
Cryptococcus neoformans in organ transplant recipients: Impact of calcineurin-inhibitor agents on mortality
Journal of Infectious Diseases, Vol. 195, Núm. 5, pp. 756-764
2006
-
Invasive aspergillosis in the recipients of liver retransplantation
Liver Transplantation, Vol. 12, Núm. 8, pp. 1205-1209
2005
-
Allograft loss in renal transplant recipients with Cryptococcus neoformans associated immune reconstitution syndrome
Transplantation, Vol. 80, Núm. 8, pp. 1131-1133